Loading page...
Loading page...
European biotech demonstrated its global relevance when BioNTech (Mainz) developed the world's first approved mRNA COVID vaccine in partnership with Pfizer.
European biotech demonstrated its global relevance when BioNTech (Mainz) developed the world's first approved mRNA COVID vaccine in partnership with Pfizer. But the continent's biotech strength extends far beyond pandemic response: over 4,500 biotech companies and SMEs operate across the EU, spanning therapeutic biotech (CureVac, Galapagos, Genmab), industrial biotech (Novozymes, Evonik Biotech), agricultural biotech (Biotalys, Agronutrition), and synthetic biology (Ginkgo Bioworks Europe, Basecamp Research).
In 2024, European biotech companies raised EUR 7.6 billion in venture capital and public offerings combined. The Innovative Health Initiative (IHI), successor to IMI2, channels EUR 2.4 billion in public-private funding toward drug discovery, diagnostics, and manufacturing innovation. Horizon Europe’s Cluster 1 (Health) and Cluster 6 (Food, Bioeconomy) together allocate over EUR 17 billion to bio-related research, making the EU the world’s most generous public funder of life-science R&D.
For biotech founders, Europe offers unmatched clinical trial infrastructure (harmonised under the Clinical Trials Regulation), world-class research hospitals, and an EMA centralised marketing authorisation that provides access to 450 million patients in a single regulatory filing. The challenge is Series B and beyond, where US biotech investors and NASDAQ listings historically absorbed European innovation — a dynamic that BioNTech’s Frankfurt listing and Galapagos’ Euronext success are beginning to reverse.
The EU pharmaceutical market is the world's second-largest (EUR 290B annually). Europe hosts 10 of the world's top 20 pharmaceutical companies and produces 40 % of global biopharmaceutical patents. The BioRegions network connects 14 life-science clusters, from the Medicon Valley (Copenhagen-Malmo) to BioValley (Basel-Strasbourg-Freiburg), creating the world's densest network of biotech talent and infrastructure.
25 EU calls mentioning Biotech are open or opening soon. The ones closing first:

Grant below €2.5M + up to €10M equity
Grant funds up to 70% of eligible innovation costs. Investment requires due diligence.
Biotech is the EIC's top-funded sector by volume. Phase II clinical-stage companies, platform technology developers, and industrial biotech scale-ups routinely receive the full EUR 17.5M blended finance.

Up to €4M
Grant for early-stage breakthrough technology research. 2027 dates are from the draft EIC Work Programme 2027 and are provisional until the official call is published.
Funds breakthrough biotech research: synthetic biology, gene therapy vectors, organ-on-chip, and AI-driven protein engineering at TRL 1-4.

Up to €2.5M
Grant to develop results from an eligible research project.
Bridges lab-stage biotech research toward IND-enabling studies, GMP manufacturing setup, and regulatory pre-submission meetings.

Topic-specific project grants
Industry, digital and space topics set their own project budgets and funding rates.
Cluster 1 (Health) funds translational research, clinical trials, and health technology assessment studies. Cluster 6 covers industrial and agricultural biotech.

Testing services & technical access
Request a service quote and check subsidy eligibility; access and discounts depend on the facility.
The Healthcare AI TEF provides real-world testing for AI-driven diagnostics, drug discovery tools, and clinical decision support systems in regulated healthcare environments.
Since 2018, 2,590 organisations received €2.3bn across 1,101 EU research and innovation projects in Biotech, including 820 SMEs. Amounts are each organisation's own share on these projects.
Specialists: at least a third of their EU projects are in this field.
428 Biotech projects started in the last three years. The latest:
GEtGutGene Editing Human Gut Microbes: Knowledge, Ethics & Responsibility Through a Multispecies Lens
Led by Universita Ca' Foscari Venezia · Italy · 2026 · Official record ↗
SAT-DesignSAT-Design – A Web Platform for Programmable Self-Assembly
Led by Universita Degli Studi di Roma la Sapienza · Italy · 2026 · Official record ↗
BactoNanoVaxRevolutionizing mRNA Cancer Vaccines with Nanosized Bacterial Outer Membrane Vesicles
Led by University of Cyprus · Cyprus · 2026 · Official record ↗
RODINCell-mediated sculptable living platforms as highly efficient hybrid units to bioengineer human microtissues
Led by Universidade de Aveiro · Portugal · 2026 · Official record ↗
BAMBiomineralization in Artificial Microcompartments
Led by Universitat des Saarlandes · Germany · 2026 · Official record ↗
ECOSHAPEThe role of growth rate density-dependence SHAPE in community assembly: ECOlogical experiments and theory
Led by United Nations Educational Scientific and Cultural Organization · France · 2026 · Official record ↗
M2-CPIDMultiscale Modelling of Microfluidic Cell Mechanoporation for Intracellular Gene Delivery
Led by Queen Mary University of London · United Kingdom · 2026 · Official record ↗
Val-PLASIntelligent Microbial Platform for Plastic Valorisation via AI-guided Synthetic Biology
Led by Bogazici Universitesi · Türkiye · 2026 · Official record ↗
Roche and Novartis HQs anchor the BioValley tri-national cluster (CH/FR/DE); 700+ life-science companies, the world's highest density of pharma R&D spending per capita.
Medicon Valley: Novo Nordisk, Lundbeck, Genmab, and 350+ biotech companies across the Oresund bridge, supported by EUR 3B annual life-science R&D spending.
AstraZeneca HQ, MRC Laboratory of Molecular Biology, and 500+ biotech companies make this Europe's densest life-science cluster outside Basel.
BioNTech R&D labs, MorphoSys, and Helmholtz Munich. The Bavarian biotech cluster has attracted EUR 2B+ in VC since 2020.
Galapagos, Pharming, and ProQR anchor the Leiden Bio Science Park — Europe's largest single-site biotech cluster with 180+ companies.
Harmonised EU-wide clinical trial authorisation through the CTIS portal. Multi-country trial applications can be submitted simultaneously, reducing approval timelines from 12+ months to 60 days for the initial assessment.
A single marketing authorisation application to EMA grants market access across all 27 EU member states plus EEA countries — covering 450 million patients in one regulatory filing.
Specific regulatory pathway for Advanced Therapy Medicinal Products (gene therapies, cell therapies, tissue-engineered products) with dedicated EMA committee (CAT) assessment.
EUR 100B mobilised toward sustainable bio-based industries. Drives funding and procurement preferences for industrial biotech solutions replacing fossil-based chemicals and materials.
Improved clinical decisions via integrating multiple data levels to overcome chemotherapy resistance in high-grade serous ovarian cancer
Denmark

Mechanism-Informed Multimodal Generative AI for Causal and Dynamical Modelling in Biomedical Research
Greece
The first manufacturing process to obtain reduced graphene oxide at large-scale
Norway
Capture and electroCONVERsion of CO2 to eThylene via an all-in-one device using Ionic LiquidS
France

Regenerative Design for the Built Environment: Integrating Participatory and Collaborative Approaches, Digital Tools, Innovative Materials, Technologies and Policies for Neighborhood Transformation
Hungary

Next generation scientists studying extracellular RNA
Switzerland
Understanding and Postponing Yeast Death to Improve Production
Slovenia

First time ultra-sensitive and simultaneous quantification of proteins, interactions
Germany
Developing new therapies for Batten disease
Sweden
MEDICIS-produced radioisotope beams for medicine
France

European Novel Drug research to Address Microbial infections and drug Resistance
France
Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)
Netherlands
Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions
Germany
MICROALGAE PROTEIN INGREDIENTS FOR THE FOOD AND FEED OF THE FUTURE
France
Modern Au-based Surfaces and Secondary ionisation for Mass Spectrometry Imaging of Small molecules
France
Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)
Netherlands
Quantitative detection of bacterial endotoxin by novel nanotechnological approaches
Italy
EuPRAXIA Early Implementation Phase Project
France
Macrocycles for Drug Discovery
Germany
Enabling the next generation in search of blood cancer cures
Spain

Breaking boundaries in cancer by targeting its microenvironment
France
Green membrane bioseparation for circular economy
Netherlands
Technologies for Ocean Sensing
Ireland
Innovative bio-based biodeGradable Recyclable safE and cirCular foOd packaging.
Italy
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
United Kingdom
Decision Support and Information Management System for Breast Cancer
Germany
First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1)
Spain

INtegrating Functional Assessment measures for Neonatal Safeguard
Netherlands
Strategies for Healing Implant-associated infections and Enhancing Longevity in Devices
Ireland
IDIBAPS Doctoral programme Yielding Novel Advancements in Medicine and Innovative Solutions
Spain
Glyco-Nanoparticles for Applications in Advance Nanomedicine
Sweden
Potential and Validation of Sustainable Natural & Advance Technologies for Water & Wastewater Treatment, Monitoring and Safe Water Reuse in India
Germany

Building a sustainable & circular economy through innovative, biobased manufacturing lines
Switzerland

Reducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models
Italy
A European training network for the discovery of neurotrophins small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation
United Kingdom
Flexible, Low-Energy, and Renewable-Integrated Production Systems for Resilient Bio-Based Industries
Netherlands

ECOPILOT: A Conversational PEF Copilot for Safe-and-Sustainable Furniture & Mattresses - From Data Gaps to Design Decisions
Spain
Empowering Innovation for a Sustainable Plastic Future
Belgium
Animal Microbiome Discovery Platform
France

Disclosing the Environmentally Sensitive brain Through Interdisciplinary training in NeuroscIence and neuropSychology
Italy
Optimising Bioeconomy Innovation Ecosystems for Substitution, Circularity, and Longevity to Decouple Sustainability Trade-offs
Netherlands
Developing a new treatment and companion diagnostic to improve outcomes for glioblastoma patients
Sweden
EU Patient- cEntric clinicAl tRial pLatform
United Kingdom

UNderstanding Lipid ImmunoMetabolIsm To trEat Disease
Austria
Biogenic Organotropic Wetsuits
Czech Republic

Exploring fungal pathogens within unexplored microbial networks
Austria

Innovative ligands for nuclear receptors to eradicate cancer relapse.
Austria
Providing risk assessments of complex real-life mixtures for the protection of Europe?s citizens and the environment
Germany

Molecular chirality tools for the study of Gluten Immunogenic Peptides and Celiac Disease: Novel therapeutic and diagnostic approaches.
Spain

Preclinical in vitro Models for the Replacement, Reduction and Refinement of Mouse Models in Preclinical Studies (PRIM-TECH3R)
Greece
Paris, France
Fund size · €300M
Seed · Series A
London, UK
Fund size · $1.24B
Series A · Series B · Growth
London, UK
Fund size · $1.3B
Series A · Series B
Rome, Italy
Fund size · €260M
Seed · Series A · Series B
Berlin, Germany
Fund size · €500M
Seed · Series A
Stockholm, Sweden
Fund size · $500M
Seed · Series A
Prague, Czechia
Fund size · €100M
Seed · Series A
Berlin, Germany
Fund size · €350M
Series A · Series B
EMA's centralised procedure covers 27+3 countries in one filing, but typically takes 210 days (vs. FDA's 180-day target). EMA requires more comparative effectiveness data and health technology assessment considerations. However, EMA's PRIME (Priority Medicines) designation accelerates promising therapies with enhanced dialogue, similar to FDA Breakthrough Therapy.
IHI is a EUR 2.4B public-private partnership replacing IMI2. It funds collaborative projects between industry, academia, and SMEs in drug discovery, diagnostics, and digital health. Biotech startups can join consortia responding to IHI calls, typically receiving EUR 0.5-2M per project for 3-5 years. Unlike EIC, IHI does not take equity.
Yes. The Clinical Trials Regulation (fully operational since January 2023) enables multinational trial applications through the CTIS portal. A single submission is assessed by a reporting member state with coordinated review by participating countries. Approval timelines are 60 days for initial assessment, making multi-country EU trials more efficient than running separate national approvals.
Yes. CRISPR and gene-editing therapeutics are explicitly funded under Horizon Europe Cluster 1 and EIC Pathfinder. European companies like CRISPR Therapeutics (originally Basel-based), Basecamp Research, and Mammoth Biosciences Europe work on gene-editing applications. The EU's regulatory framework for ATMPs provides a clear (if demanding) path to market for gene therapies.